Pharmaceutical intermediates
Relugolix Intermediates
7 pharmaceutical intermediates for Relugolix. Indication: Prostate Cancer; Leiomyoma.
About Relugolix
- Originator
- Takeda Yakuhin Kogyo Co.,Ltd
- Indication
- Prostate Cancer; Leiomyoma
- Approved Date
- 12/18/2020
- NCE Patent
- 12/18/2025
- DS/DP
- 01/28/2026
Available intermediates
7 intermediates currently listed for Relugolix. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid | 1589503-95-6 | / | / |
| 3-AMINO-6-METHOXYPYRIDAZINE | 7252-84-8 | / | / |
| ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate | 308831-94-9 | / | / |
| 2-AcetaMido-4,5-diMethylthiophene-3-carboxylic acid | 2591260-09-0 | / | / |
| 3-Thiophenecarboxylic acid, 2-[[(2,6-difluorophenyl)methyl](propoxycarbonyl)amino]-4-[(dimethylamino)methyl]-5-(4-nitrophenyl)-, ethyl ester | 2591260-08-9 | / | / |
| 3-Thiophenecarboxylic acid,5-(4-aminophenyl)-2-[[(2,6-difluorophenyl)methyl](ethoxycarbonyl)amino]-4-[(dimethylamino)methyl]-,ethylester, hydrochloride (1:2) | 2768834-98-4 | / | / |
| 2-[(2,6-Difluorobenzyl)ethoxycarbonylamino]-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylic acid ethyl ester | 1589503-97-8 | / | / |
Other programs under R
Building toward Relugolix?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →